



## **Kadmon Acquires First-in-Class Ras Antagonist from Concordia Pharmaceuticals**

**NEW YORK and MIAMI, January 9, 2012** – Kadmon Corporation, LLC, today announced the signing of an asset purchase agreement with Concordia Pharmaceuticals, Inc., under which Kadmon has acquired all rights to salirasib, a Phase 2, novel, orally available, small molecule therapeutic in development for the treatment of solid tumors. Financial terms of the agreement were not disclosed.

Salirasib (KD032) is a first-in-class direct Ras antagonist designed to inhibit overactive cell growth in cancer caused by various Ras proteins, including H-Ras and K-Ras. Constitutively active Ras, caused by mutations in the Ras family of proto-oncogenes, is present in one-third of human cancers, making it the single most prevalent abnormality of human proto-oncogenes. Mutant forms of Ras are found in approximately 35% to 40% of colorectal cancers, 70% to 90% of pancreatic cancers, and 20% to 25% of non-small cell lung cancers. KD032 has demonstrated significant reduction of Ras levels in a wide array of established cancer models. Additionally, KD032 has demonstrated promising clinical activity and tolerability in combination with gemcitabine in a Phase 1/2 trial in advanced pancreatic cancer and as monotherapy in non-small cell lung cancer.

“KD032 is a valuable addition to our pipeline, as it fits with our development philosophy of concentrating on novel therapeutics and therapeutic combinations which can materially impact the treatment of serious diseases,” stated Samuel D. Waksal, Ph.D., Chairman and Chief Executive Officer of Kadmon. “KD032 antagonizes a family of proteins that sits at the center of the cell’s proliferation mechanism and is responsible for advancing the signals currently targeted by some of the most important anti-cancer therapies, including EGFR antagonists. Its use in combination with these therapies holds the potential to dramatically affect the resistance mechanisms of some of the most prevalent cancers, including K-Ras mutant colorectal cancer. We look forward to the further development of KD032.”

“Kadmon is developing an impressive pipeline of novel therapeutics, and we are proud to see KD032 now included among its oncology product candidates,” stated Reginald Hardy, President of Concordia. “Our agreement with Kadmon recognizes KD032’s potential and provides the resources, leadership and expertise to rapidly advance this program through the clinic.”

MTS Health Partners L.P. acted as financial advisor to Concordia.

### **About Kadmon Corporation**

Kadmon Corporation, LLC is a global company built on a 21st-century paradigm for the translation of innovative science into treatment. The company currently offers products and services for the treatment and management of hepatitis C. Kadmon is pioneering medicines in oncology, infectious diseases, immunology and neurodegenerative diseases by using emerging concepts in molecular biology

and genomics to develop therapies that target the metabolomic and signaling pathways associated with disease. For more information, visit [www.kadmon.com](http://www.kadmon.com).

**Contact Information**

For Kadmon Corporation, LLC:

David Pitts

Argot Partners

212.600.1902

[david@argotpartners.com](mailto:david@argotpartners.com)